A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial intelligence, the MECHanistic PATHology (MechPath) approach allows researchers to identify patterns and make reliable predictions without relying on animal testing.
Key results so far:
Human cells used in lab models appear to retain a “disease memory,” continuing to respond as if they were still in the body, offering more realistic models for conditions like fibrosis.
The newly developed CELLS-PATH validation tools help lab-grown models gain approval faster, paving the way for wider adoption in drug research.
Dura Vermeer Commercieel Vastgoed and Cellares has signed a long-term lease for a new IDMO Smart Factory in building Nexus (9,741 sqm LFA) at Leiden Bio Science Park. The...
The successful program for stimulating digitization in small and medium-sized businesses in the Leiden and Katwijk region is getting a sequel. Key Region Leiden, in cooperation...
Leiden, 8 January 2026 – Two scientific projects from Leiden University and LUMC have received funding from Open Science NL. The aim is to make science more accessible to...